Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1994 Nov;71(5):457–462. doi: 10.1136/adc.71.5.457

Anthracyclines: cardiotoxicity and its prevention.

J P Hale 1, I J Lewis 1
PMCID: PMC1030067  PMID: 7826122

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bielack S. S., Erttmann R., Winkler K., Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989 May;25(5):873–882. doi: 10.1016/0277-5379(89)90135-1. [DOI] [PubMed] [Google Scholar]
  2. Bodley A., Liu L. F., Israel M., Seshadri R., Koseki Y., Giuliani F. C., Kirschenbaum S., Silber R., Potmesil M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 1989 Nov 1;49(21):5969–5978. [PubMed] [Google Scholar]
  3. Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P. Drugs ten years later: epirubicin. Ann Oncol. 1993 May;4(5):359–369. doi: 10.1093/oxfordjournals.annonc.a058514. [DOI] [PubMed] [Google Scholar]
  4. Borden E. C., Amato D. A., Rosenbaum C., Enterline H. T., Shiraki M. J., Creech R. H., Lerner H. J., Carbone P. P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987 Jun;5(6):840–850. doi: 10.1200/JCO.1987.5.6.840. [DOI] [PubMed] [Google Scholar]
  5. Bristow M. R., Billingham M. E., Mason J. W., Daniels J. R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun;62(6):873–879. [PubMed] [Google Scholar]
  6. Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb;88(2):168–175. doi: 10.7326/0003-4819-88-2-168. [DOI] [PubMed] [Google Scholar]
  7. Bu'Lock F. A., Gabriel H. M., Oakhill A., Mott M. G., Martin R. P. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. 1993 Aug;70(2):185–188. doi: 10.1136/hrt.70.2.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Casper E. S., Gaynor J. J., Hajdu S. I., Magill G. B., Tan C., Friedrich C., Brennan M. F. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991 Sep 15;68(6):1221–1229. doi: 10.1002/1097-0142(19910915)68:6<1221::aid-cncr2820680607>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  9. Doroshow J. H., Locker G. Y., Myers C. E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980 Jan;65(1):128–135. doi: 10.1172/JCI109642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dresdale A., Bonow R. O., Wesley R., Palmeri S. T., Barr L., Mathison D., D'Angelo T., Rosenberg S. A. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer. 1983 Jul 1;52(1):51–60. doi: 10.1002/1097-0142(19830701)52:1<51::aid-cncr2820520111>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  11. Gabizon A., Peretz T., Sulkes A., Amselem S., Ben-Yosef R., Ben-Baruch N., Catane R., Biran S., Barenholz Y. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1795–1803. doi: 10.1016/0277-5379(89)90350-7. [DOI] [PubMed] [Google Scholar]
  12. Gilladoga A. C., Manuel C., Tan C. T., Wollner N., Sternberg S. S., Murphy M. L. The cardiotoxicity of adriamycin and daunomycin in children. Cancer. 1976 Feb;37(2 Suppl):1070–1078. doi: 10.1002/1097-0142(197602)37:2+<1070::aid-cncr2820370814>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Goorin A. M., Chauvenet A. R., Perez-Atayde A. R., Cruz J., McKone R., Lipshultz S. E. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990 Jan;116(1):144–147. doi: 10.1016/s0022-3476(05)81668-3. [DOI] [PubMed] [Google Scholar]
  14. Hausdorf G., Morf G., Beron G., Erttmann R., Winkler K., Landbeck G., Keck E. W. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 1988 Oct;60(4):309–315. doi: 10.1136/hrt.60.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hellmann K., Newton K. A., Whitmore D. N., Hanham I. W., Bond J. V. Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma. Br Med J. 1969 Mar 29;1(5647):822–824. doi: 10.1136/bmj.1.5647.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Herman E. H., Mhatre R. M., Lee I. P., Waravdekar V. S. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med. 1972 May;140(1):234–239. doi: 10.3181/00379727-140-36432. [DOI] [PubMed] [Google Scholar]
  17. Herman E. H., Rahman A., Ferrans V. J., Vick J. A., Schein P. S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983 Nov;43(11):5427–5432. [PubMed] [Google Scholar]
  18. Holcenberg J. S., Tutsch K. D., Earhart R. H., Ungerleider R. S., Kamen B. A., Pratt C. B., Gribble T. J., Glaubiger D. L. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep. 1986 Jun;70(6):703–709. [PubMed] [Google Scholar]
  19. Keizer H. G., Pinedo H. M., Schuurhuis G. J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47(2):219–231. doi: 10.1016/0163-7258(90)90088-j. [DOI] [PubMed] [Google Scholar]
  20. Klewer S. E., Goldberg S. J., Donnerstein R. L., Berg R. A., Hutter J. J., Jr Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992 Feb;19(2):394–401. doi: 10.1016/0735-1097(92)90497-b. [DOI] [PubMed] [Google Scholar]
  21. Launchbury A. P., Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228. doi: 10.1016/0305-7372(93)90036-q. [DOI] [PubMed] [Google Scholar]
  22. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  23. Legha S. S., Benjamin R. S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S. L., Blumenschein G. R., Freireich E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–139. doi: 10.7326/0003-4819-96-2-133. [DOI] [PubMed] [Google Scholar]
  24. Lipshultz S. E., Colan S. D., Gelber R. D., Perez-Atayde A. R., Sallan S. E., Sanders S. P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21;324(12):808–815. doi: 10.1056/NEJM199103213241205. [DOI] [PubMed] [Google Scholar]
  25. Marchandise B., Schroeder E., Bosly A., Doyen C., Weynants P., Kremer R., Pouleur H. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989 Jul;118(1):92–98. doi: 10.1016/0002-8703(89)90077-x. [DOI] [PubMed] [Google Scholar]
  26. Monti E., Sinha B. K. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Commun. 1990;2(4):145–149. doi: 10.3727/095535490820874551. [DOI] [PubMed] [Google Scholar]
  27. Myers C. E., McGuire W. P., Liss R. H., Ifrim I., Grotzinger K., Young R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. doi: 10.1126/science.877547. [DOI] [PubMed] [Google Scholar]
  28. Palmeri S. T., Bonow R. O., Myers C. E., Seipp C., Jenkins J., Green M. V., Bacharach S. L., Rosenberg S. A. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986 Sep 15;58(7):607–613. doi: 10.1016/0002-9149(86)90284-5. [DOI] [PubMed] [Google Scholar]
  29. Pegelow C. H., Popper R. W., de Wit S. A., King O. Y., Wilbur J. R. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol. 1984 May;2(5):443–446. doi: 10.1200/JCO.1984.2.5.443. [DOI] [PubMed] [Google Scholar]
  30. Rajagopalan S., Politi P. M., Sinha B. K., Myers C. E. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988 Sep 1;48(17):4766–4769. [PubMed] [Google Scholar]
  31. Schwartz C. L., Hobbie W. L., Truesdell S., Constine L. C., Clark E. B. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993 Oct;11(10):1906–1910. doi: 10.1200/JCO.1993.11.10.1906. [DOI] [PubMed] [Google Scholar]
  32. Schwartz R. G., McKenzie W. B., Alexander J., Sager P., D'Souza A., Manatunga A., Schwartz P. E., Berger H. J., Setaro J., Surkin L. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun;82(6):1109–1118. doi: 10.1016/0002-9343(87)90212-9. [DOI] [PubMed] [Google Scholar]
  33. Sehested M., Jensen P. B., Sørensen B. S., Holm B., Friche E., Demant E. J. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol. 1993 Aug 3;46(3):389–393. doi: 10.1016/0006-2952(93)90514-w. [DOI] [PubMed] [Google Scholar]
  34. Shapira J., Gotfried M., Lishner M., Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990 Feb 15;65(4):870–873. doi: 10.1002/1097-0142(19900215)65:4<870::aid-cncr2820650407>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  35. Shenkenberg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986 Jul;105(1):67–81. doi: 10.7326/0003-4819-105-1-67. [DOI] [PubMed] [Google Scholar]
  36. Silber J. H., Jakacki R. I., Larsen R. L., Goldwein J. W., Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21(7):477–479. doi: 10.1002/mpo.2950210704. [DOI] [PubMed] [Google Scholar]
  37. Simone J. V., Meyer W. H., Link M. P. Osteosarcoma: good news despite crude tools. J Clin Oncol. 1992 Jan;10(1):1–2. doi: 10.1200/JCO.1992.10.1.1. [DOI] [PubMed] [Google Scholar]
  38. Speyer J. L., Green M. D., Dubin N., Blum R. H., Wernz J. C., Roses D., Sanger J., Muggia F. M. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med. 1985 Apr;78(4):555–563. doi: 10.1016/0002-9343(85)90395-x. [DOI] [PubMed] [Google Scholar]
  39. Speyer J. L., Green M. D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V., Stecy P., Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988 Sep 22;319(12):745–752. doi: 10.1056/NEJM198809223191203. [DOI] [PubMed] [Google Scholar]
  40. Steinherz L. J., Graham T., Hurwitz R., Sondheimer H. M., Schwartz R. G., Shaffer E. M., Sandor G., Benson L., Williams R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992 May;89(5 Pt 1):942–949. [PubMed] [Google Scholar]
  41. Steinherz L. J., Steinherz P. G., Tan C. T., Heller G., Murphy M. L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 Sep 25;266(12):1672–1677. [PubMed] [Google Scholar]
  42. Tan C., Tasaka H., Yu K. P., Murphy M. L., Karnofsky D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333–353. doi: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  43. Tannir N., Yap H. Y., Hortobagyi G. H., Hug V., Buzdar A. U., Blumenschein G. R. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1039–1041. [PubMed] [Google Scholar]
  44. Torti F. M., Bristow M. R., Howes A. E., Aston D., Stockdale F. E., Carter S. K., Kohler M., Brown B. W., Jr, Billingham M. E. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec;99(6):745–749. doi: 10.7326/0003-4819-99-6-745. [DOI] [PubMed] [Google Scholar]
  45. Treat J., Greenspan A., Forst D., Sanchez J. A., Ferrans V. J., Potkul L. A., Woolley P. V., Rahman A. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706–1710. doi: 10.1093/jnci/82.21.1706. [DOI] [PubMed] [Google Scholar]
  46. Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]
  47. Von Hoff D. D., Rozencweig M., Layard M., Slavik M., Muggia F. M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977 Feb;62(2):200–208. doi: 10.1016/0002-9343(77)90315-1. [DOI] [PubMed] [Google Scholar]
  48. Weesner K. M., Bledsoe M., Chauvenet A., Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991 Jul 15;68(2):435–438. doi: 10.1002/1097-0142(19910715)68:2<435::aid-cncr2820680237>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  49. Weiss A. J., Manthel R. W. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. 1977 Nov;40(5):2046–2052. doi: 10.1002/1097-0142(197711)40:5<2046::aid-cncr2820400508>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  50. Zalupski M., Metch B., Balcerzak S., Fletcher W. S., Chapman R., Bonnet J. D., Weiss G. R., Ryan J., Benjamin R. S., Baker L. H. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Jul 3;83(13):926–932. doi: 10.1093/jnci/83.13.926. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES